- MA1-23152 - Invitrogen Antibodies ATM antibody

Submitted references DNA-PK Inhibitor, M3814, as a New Combination Partner of Mylotarg in the Treatment of Acute Myeloid Leukemia.

Carr MI, Zimmermann A, Chiu LY, Zenke FT, Blaukat A, Vassilev LT
Frontiers in oncology 2020;10:127

Repair genes expression profile of MLH1, MSH2 and ATM in the normal oral mucosa of chronic smokers.

Alves MG, Carta CF, de Barros PP, Issa JS, Nunes FD, Almeida JD
Archives of oral biology 2017 Jan;73:60-65

A novel porcine model of ataxia telangiectasia reproduces neurological features and motor deficits of human disease.

Beraldi R, Chan CH, Rogers CS, Kovács AD, Meyerholz DK, Trantzas C, Lambertz AM, Darbro BW, Weber KL, White KA, Rheeden RV, Kruer MC, Dacken BA, Wang XJ, Davis BT, Rohret JA, Struzynski JT, Rohret FA, Weimer JM, Pearce DA
Human molecular genetics 2015 Nov 15;24(22):6473-84

No comments: Submit comment

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western blot analysis of ATM using A) 30 µg NT2D1 whole cell lysate (B) 30 µg PC-3 whole cell lysate and C) 30 µg SK-N-SH whole cell lysate. Samples were loaded onto a 5% SDS-PAGE gel and probed with an ATM monoclonal antibody (Product # MA1-23152) at a dilution of 1:1000.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western blot analysis of ATM using A) 30 µg U87-MG whole cell lysate (B) 30 µg SK-N-SH whole cell lysate (C) 30 µg IMR32 whole cell lysate and D) 30 µg SK-N-AS whole cell lysate. Samples were loaded onto a 5% SDS-PAGE gel and probed with an ATM monoclonal antibody (Product # MA1-23152) at a dilution of 1:1000.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western blot analysis of ATM in Raji whole cell extract using an ATM monoclonal antibody (Product # MA1-23152).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western blot analysis of ATM was performed by separating 30 µg of HeLa whole cell extract and nuclear extracts by 5% SDS-PAGE. Proteins were transferred to a membrane and probed with a ATM Monoclonal Antibody (2C1) (Product # MA1-23152) at a dilution of 1:500. The HRP-conjugated anti-mouse IgG antibody was used to detect the primary antibody.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Knockout of ATM was achieved by CRISPR-Cas9 genome editing using LentiArray™ Lentiviral sgRNA (Product # A32042, Assay ID CRISPR901163_LV) and LentiArray Cas9 Lentivirus (Product # A32064). Western blot analysis of ATM was performed by loading 30 µg of HeLa Wild Type (Lane 1), HeLa Cas9 (Lane 2) andHeLa ATM KO (Lane 3) whole cell extracts. The samples were electrophoresed using NuPAGE™ 3-8% Tris-Acetate Protein Gel (Product # EA0378BOX). Resolved proteins were then transferred onto a nitrocellulose membrane (Product # IB23001) by iBlot® 2 Dry Blotting System (Product # IB21001). The blot was probed with Anti-ATM Monoclonal Antibody (2C1) (Product # MA1-23152, 1:500 dilution) and Goat anti-Mouse IgG (H+L) Superclonal™ Recombinant Secondary Antibody, HRP (Product # A28177, 1:8,000 dilution) using the iBright FL 1000 (Product # A32752). Chemiluminescent detection was performed using Novex® ECL Chemiluminescent Substrate Reagent Kit (Product # WP20005). Loss of signal upon CRISPR mediated knockout (KO) using the LentiArray™ CRISPR product line confirms that antibody is specific to ATM. Uncharacterized bands was observed in all the samples at 235 and 410 kDa.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western Blot analysis of ATM was performed by separating 30 µg of whole cell extract by 5% SDS-PAGE. Proteins were transferred to a membrane and probed with a ATM Monoclonal Antibody (2C1) (Product # MA1-23152) at a dilution of 1:1000.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunoprecipitation and Western blot of human ATM protein using anti-ATM 2C1 monoclonal antibody (Product # MA1-23152).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemistry (Paraffin) analysis of ATM was performed in paraffin-embedded human breast carcinoma tissue using ATM Monoclonal Antibody (2C1) (Product # MA1-23152) at a dilution of 1:100. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemistry (Paraffin) analysis. Human Kidney (formalin-fixed, paraffin-embedded) stained with ATM Monoclonal Antibody (2C1) (Product # MA1-23152) at 5 µg/mL followed by biotinylated anti-mouse IgG secondary antibody, alkaline phosphatase-streptavidin and chromogen.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemistry (Paraffin) analysis. Human Testis (formalin-fixed, paraffin-embedded) stained with ATM Monoclonal Antibody (2C1) (Product # MA1-23152) at 5 µg/mL followed by biotinylated anti-mouse IgG secondary antibody, alkaline phosphatase-streptavidin and chromogen.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 M3814 overactivates p53 in response to calicheamicin in AML cells. (A) Relative gene expression analysis of key p53 transcriptional targets, Mdm2, p21 and Puma, in MV4-11 (p53 wild-type) cells treated with DMSO, calicheamicin (0.5 or 1.0 pM), or M3814 (300 or 1,000 nM) alone or in combination. Relative expression determined by the 2 (-DeltaDeltaCt) method with GAPDH reference. (B) Western blot analysis of ATM and p53 pathway proteins as well as apoptotic indicators at 6, 24, 48, and 96 h in lysates of MV4-11 cells treated with vehicle, M3814 (1 muM), calicheamicin (1pM), or the combination of calicheamicin (1 pM), and M3814 (1 muM). (C) Relative gene expression analysis at 6 and 24 h of key p53 transcriptional targets, Mdm2, p21, and Puma, in MV4-11 (p53 wild-type) cells treated with DMSO, M3814 (1 muM), M3541 (1 muM), calicheamicin (1.0 pM), calicheamicin (1 pM) + M3814 (1 muM), or calicheamicin (1 pM) + M3814 (1 muM) + M3541 (1 muM). * P < 0.05, ** P < 0.01, *** P < 0.001.

MA1-23152

Antibody data